Cooley advised Bellicum Pharmaceuticals on its $69 million public offering of 5,750,000 shares of common stock, including the exercise by the underwriters of their option to…
Bellicum’s $69 Million Public Offering
Cooley advised Bellicum Pharmaceuticals on its $69 million public offering of 5,750,000 shares of common stock, including the exercise by the underwriters of their option to…